ReWalk(US:LFWD) ZACKSยท2025-09-09 13:45Core Insights - Lifeward Ltd. (LFWD) has received CE mark approval for the ReWalk 7 Personal Exoskeleton, allowing for commercial sale in Europe, which constitutes approximately 40% of the company's exoskeleton sales [1][7] - The ReWalk 7 features enhancements such as cloud connectivity, push-button control, customizable walking speeds, and the ability to navigate stairs and curbs, making it unique in the market [2][7] - The company has established supply contracts with major insurance carriers in Germany, covering about 45% of individuals with statutory health insurance, facilitating reimbursement for the exoskeletons [3] Financial Performance - Following the CE approval announcement, Lifeward's shares rose by 2.2% in after-market trading, although the stock has declined by 68.9% year-to-date, contrasting with a 20.4% growth in the industry and a 10.8% gain in the S&P 500 [4] - The recent approvals and improved cash burn rate due to operational efficiencies may positively impact future revenues and share price [5] Product Development and Manufacturing - The ReWalk 7 was launched in the U.S. in April, with over 20 units installed, marking the highest quarterly total for Medicare beneficiaries since the fee schedule was established [8] - The company transitioned to in-house manufacturing of the ReWalk, resulting in cost savings, improved quality control, and greater production flexibility [9] Research and Partnerships - Lifeward concluded a research program under the Israel Innovation Authority's MAGNET incentive program, demonstrating a proof-of-concept prototype integrating AI for autonomous decision-making in future ReWalk models [10] - The company expanded its partnership with SportsMed Products Ltd. for distributing its AlterG product portfolio in the UAE and the Gulf Cooperation Council [11]